ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2674

Patient Global Assessment in Evaluating Boolean-Based Remission in Rheumatoid Arthritis-Is It Really Required Instead of Physician Global Assessment? a Comparative Study with Ultrasound

Gulsen Ozen1, Ali Ugur Unal1, Atakan Topcu2, Pamir Atagunduz1, Haner Direskeneli1 and Nevsun Inanc1, 1Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: patient-reported outcome measures, remission, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient global assessment (PtGA) is included in all the current remission definitions for RA despite the fact that PtGA is not exclusively related to disease activity and may be influenced by noninflammatory or psychological processess.  In this study in order to objectively identify whether patient’s assessment is better than physician’s (Ph) or not, we compared disease activities assessed with ultrasound (US) of Boolean remission patients with PtGA and Boolean remission patients with PhGA but not PtGA.

Methods: RA patients in clinical remission (DAS28-ESR<2.6) for at least 3 months were included. Boolean based remission definition and modified versions by substitution of PtGA with PhGA and by omitting PtGA were determined. A standard gray scale (GS)  and power Doppler (PD) US examination of 28 joints (included in DAS28) for the presence of synovitis was performed by an experienced sonographer (NI) blinded to clinical data. US synovitis GS and PD signals were semiquantitatively graded from 0 to 3 and were recorded as sum scores of PD and GS, respectively.

Results: A total of 55 out of 302 RA patients (18.2%) in DAS28 remission were enrolled (F/M=35/20, mean age 52.2±12.0, disease duration 11.011.0±6.5 years, bDMARDs 43.6%,  RF/Anti-CCP positivity 76.4%). Of 55 patients, 25 (45.5%) fulfilled the Boolean criteria. When PtGA was substituted with PhGA,  remission rate increased to 72.7% (n=40) and when PtGA was omitted remission rate increased to 89.1% (n=49) (P<0.001 for both). Regarding US disease activity no PD, no GS and no PD+GS signals were observed in 9 (36%) vs 12 (30%), 7 (28%) vs 8 (20%) and 6 (24%) vs 7 (17.5%)  patients in Boolean remission with PtGA and PhGA, respectively (P>0.05 for all).  When PD and GS signals ≥ grade 2 were taken into account, % of patients without PD, GS or both signals were also similar (respectively, 16 [64%] vs 25 [62.5%], 12 [48%] vs 18 [45%] and 12 [48%] vs 17 [42.5%]). US disease activity parameters of Boolean PtGA remission and nonremission patients were compared as well, no significant difference was observed. On the other hand patients in Boolean PhGA remission had significantly lower PD scores (without grade 1) compared to Boolean PhGA nonremission (Table 1). In comparison of US disease activity of patients in Boolean PtGA remission and in Boolean remission with PhGA but not PtGA, the median PD and GS synovitis sum scores and the % of patients with no PD or GS signals were not statistically different.  

Conclusion: RA patients in Boolean remission with PhGA do not have higher disease activity that is verified by US, compared to patients in Boolean remission with PtGA. Furthermore Boolean remission with PhGA better differentiates patients with US evinced inflammation. These data suggest that PtGA might be substituted with PhGA in Boolean criteria. Prospective follow up and recruitment of more patients will clarify the consistency of these results over time and impact of this substitution on functionality.    

 

Table 1. US disease activity parameters of remission and nonremission patients according to Boolean based criteria with PtGA and PhGA*

 

Boolean remission with PtGA (n=25)

Boolean non-remission with PtGA (n=30)

P value

Boolean remission with PhGA (n=40)

Boolean non-remission with PhGA (n=15)

P value

PD synovitis sum score (0-84)

1 (0-4.5)

2.5 (0-6.2)

0.26

1 (0-4)

4 (0-7)

0.26

PD synovitis sum scores (without counting grade 1 signals)

0 (0-3)

1 (0-6)

0.20

0 (0-3.5)

4 (0-6)

0.045

GS synovitis sum score (0-84)

3 (0-6.5)

4 (1-8.2)

0.32

3.5 (1-8)

4 (1-9)

0.59

GS synovitis sum scores (without counting grade 1 signals)

2 (0-5)

2 (0-7.2)

0.39

2 (0-6)

4 (0-8)

0.58

US joint count with PD signal

(0-28)

1 (0-3)

2 (0-3.2)

0.32

1 (0-3)

2 (0-4)

0.36

US joint count with PD signal (without counting grade 1 signals)

0 (0-1.5)

0.5 (0-3)

0.21

0 (0-1.7)

2 (0-3)

0.090

US joint count with GS signal

(0-28)

2 (0-4.5)

3 (1-4)

0.37

2 (1-4)

3 (1-4)

0.73

US joint count with GS signal (without counting grade 1 signals)

1 (0-2.5)

1 (0-3.2)

0.39

1 (0-3)

3 (1-4)

0.61

USDAS28PD

2.35 (1.82-2.91)

2.55 (2.26-2.8)

0.32

2.47 (1.99-2.83)

2.50 (2.31-2.83)

0.35

USDAS28GS

2.35 (1.88-3.03)

2.69 (2.3-2.9)

0.31

2.54 (2.02-2.99)

2.60 (2.40-2.90)

0.49

*The values were presented as median (25-75).

 


Disclosure: G. Ozen, None; A. U. Unal, None; A. Topcu, None; P. Atagunduz, None; H. Direskeneli, None; N. Inanc, None.

To cite this abstract in AMA style:

Ozen G, Unal AU, Topcu A, Atagunduz P, Direskeneli H, Inanc N. Patient Global Assessment in Evaluating Boolean-Based Remission in Rheumatoid Arthritis-Is It Really Required Instead of Physician Global Assessment? a Comparative Study with Ultrasound [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/patient-global-assessment-in-evaluating-boolean-based-remission-in-rheumatoid-arthritis-is-it-really-required-instead-of-physician-global-assessment-a-comparative-study-with-ultrasound/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-global-assessment-in-evaluating-boolean-based-remission-in-rheumatoid-arthritis-is-it-really-required-instead-of-physician-global-assessment-a-comparative-study-with-ultrasound/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology